NO763846L - - Google Patents
Info
- Publication number
- NO763846L NO763846L NO763846A NO763846A NO763846L NO 763846 L NO763846 L NO 763846L NO 763846 A NO763846 A NO 763846A NO 763846 A NO763846 A NO 763846A NO 763846 L NO763846 L NO 763846L
- Authority
- NO
- Norway
- Prior art keywords
- less
- carbon atoms
- formula
- rifamycin
- compounds
- Prior art date
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 42
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- -1 nitro- Chemical class 0.000 claims description 11
- 239000011701 zinc Substances 0.000 claims description 11
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229930189077 Rifamycin Natural products 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229960003292 rifamycin Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- SMPJCQGFZSDIHE-GVDHMVJUSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-amino-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl] acetate Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C(N)=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O SMPJCQGFZSDIHE-GVDHMVJUSA-N 0.000 description 13
- 238000000862 absorption spectrum Methods 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 5
- 235000010378 sodium ascorbate Nutrition 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229940109171 rifamycin sv Drugs 0.000 description 2
- 229940081192 rifamycins Drugs 0.000 description 2
- 239000004296 sodium metabisulphite Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- JMPVYNJKWJGXEY-UHFFFAOYSA-N 1-phenyltetrazole-5-carbaldehyde Chemical compound O=CC1=NN=NN1C1=CC=CC=C1 JMPVYNJKWJGXEY-UHFFFAOYSA-N 0.000 description 1
- LNROIXNEIZSESG-UHFFFAOYSA-N 2,5-dimethyl-1-phenylpyrrole-3-carbaldehyde Chemical compound CC1=CC(C=O)=C(C)N1C1=CC=CC=C1 LNROIXNEIZSESG-UHFFFAOYSA-N 0.000 description 1
- OACPOWYLLGHGCR-UHFFFAOYSA-N 2-chloro-6-fluorobenzaldehyde Chemical compound FC1=CC=CC(Cl)=C1C=O OACPOWYLLGHGCR-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- RKXCKEHBMLDWET-UHFFFAOYSA-N 3,6-dihydro-2h-pyran-5-carbaldehyde Chemical compound O=CC1=CCCOC1 RKXCKEHBMLDWET-UHFFFAOYSA-N 0.000 description 1
- OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 description 1
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical compound O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT05240/75A IT1068367B (it) | 1975-11-12 | 1975-11-12 | 3 aldimino rifamicine ad alta attivita antibiotica loro derivati e procedimento per ottenerle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO763846L true NO763846L (fr) | 1977-05-13 |
Family
ID=11119820
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO763845A NO763845L (fr) | 1975-11-12 | 1976-11-11 | |
| NO763846A NO763846L (fr) | 1975-11-12 | 1976-11-11 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO763845A NO763845L (fr) | 1975-11-12 | 1976-11-11 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US4124585A (fr) |
| JP (2) | JPS5262298A (fr) |
| AT (2) | AT349142B (fr) |
| AU (2) | AU508954B2 (fr) |
| BE (2) | BE848185A (fr) |
| CA (2) | CA1074792A (fr) |
| CH (2) | CH626367A5 (fr) |
| DE (2) | DE2651317A1 (fr) |
| DK (2) | DK509076A (fr) |
| ES (2) | ES453278A1 (fr) |
| FI (2) | FI763218A (fr) |
| FR (2) | FR2331562A1 (fr) |
| GB (2) | GB1561300A (fr) |
| HU (2) | HU173694B (fr) |
| IL (1) | IL50820A (fr) |
| IT (1) | IT1068367B (fr) |
| NL (2) | NL7612639A (fr) |
| NO (2) | NO763845L (fr) |
| PT (2) | PT65831B (fr) |
| SE (1) | SE7612565L (fr) |
| SU (2) | SU674676A3 (fr) |
| YU (2) | YU274476A (fr) |
| ZA (2) | ZA766771B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1567881A (en) * | 1978-02-07 | 1980-05-21 | Archifar Lab Chim Farm | Rifamycin compounds |
| DE2943412A1 (de) * | 1979-10-26 | 1981-05-07 | Naamloze Vennootschap Klippan S.A., Leeuwen | Verriegelungsvorrichtung fuer einen gurtaufroller bei sicherheitsgurten |
| IT1135270B (it) * | 1980-04-12 | 1986-08-20 | Erba Farmitalia | 3-amidino-ansamicine |
| IT1201963B (it) * | 1983-03-24 | 1989-02-02 | Prodotti Antibiotici Spa | Derivati delle rifamicine e procedimento per la loro preparazione |
| DE10216719B4 (de) * | 2002-04-10 | 2007-09-20 | Helmholtz-Zentrum Für Umweltforschung Gmbh - Ufz | N-(3-Rifamycinyl)carbamate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Behandlung und Verhütung von Tuberkulose |
| CN102942574B (zh) * | 2012-11-29 | 2015-06-03 | 郑州民众制药有限公司 | 一种生产利福霉素s的新工艺 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH536851A (de) * | 1966-10-25 | 1973-05-15 | Ciba Geigy Ag | Verfahren zur Herstellung neuer antibiotisch wirksamer Verbindungen der Rifamycinreihen |
| US3829417A (en) * | 1972-12-29 | 1974-08-13 | Lepetit Spa | Imidazole substituted rifamycins |
| IT1053787B (it) * | 1974-10-29 | 1981-10-10 | Pastori A | Macrolidi azotati e loro preparazione |
-
1975
- 1975-11-12 IT IT05240/75A patent/IT1068367B/it active
-
1976
- 1976-11-01 GB GB45271/76A patent/GB1561300A/en not_active Expired
- 1976-11-01 GB GB45270/76A patent/GB1561299A/en not_active Expired
- 1976-11-02 IL IL50820A patent/IL50820A/xx unknown
- 1976-11-03 US US05/738,352 patent/US4124585A/en not_active Expired - Lifetime
- 1976-11-03 US US05/738,358 patent/US4124586A/en not_active Expired - Lifetime
- 1976-11-09 YU YU02744/76A patent/YU274476A/xx unknown
- 1976-11-09 AU AU19434/76A patent/AU508954B2/en not_active Expired
- 1976-11-09 YU YU02745/76A patent/YU274576A/xx unknown
- 1976-11-09 CA CA265,218A patent/CA1074792A/fr not_active Expired
- 1976-11-09 AU AU19435/76A patent/AU508684B2/en not_active Expired
- 1976-11-09 CA CA265,217A patent/CA1074791A/fr not_active Expired
- 1976-11-10 FI FI763218A patent/FI763218A/fi not_active Application Discontinuation
- 1976-11-10 DE DE19762651317 patent/DE2651317A1/de not_active Withdrawn
- 1976-11-10 BE BE172230A patent/BE848185A/fr unknown
- 1976-11-10 DE DE19762651318 patent/DE2651318A1/de not_active Withdrawn
- 1976-11-10 HU HU76AI266A patent/HU173694B/hu unknown
- 1976-11-10 BE BE172231A patent/BE848186A/fr unknown
- 1976-11-10 HU HU76AI267A patent/HU173695B/hu unknown
- 1976-11-10 FI FI763219A patent/FI763219A/fi not_active Application Discontinuation
- 1976-11-11 AT AT838876A patent/AT349142B/de not_active IP Right Cessation
- 1976-11-11 PT PT65831A patent/PT65831B/pt unknown
- 1976-11-11 NO NO763845A patent/NO763845L/no unknown
- 1976-11-11 ZA ZA766771A patent/ZA766771B/xx unknown
- 1976-11-11 AT AT838776A patent/AT349141B/de not_active IP Right Cessation
- 1976-11-11 CH CH1419576A patent/CH626367A5/it not_active IP Right Cessation
- 1976-11-11 ZA ZA766770A patent/ZA766770B/xx unknown
- 1976-11-11 NO NO763846A patent/NO763846L/no unknown
- 1976-11-11 DK DK509076A patent/DK509076A/da unknown
- 1976-11-11 CH CH1419476A patent/CH627470A5/it not_active IP Right Cessation
- 1976-11-11 PT PT65830A patent/PT65830B/pt unknown
- 1976-11-11 SE SE7612565A patent/SE7612565L/xx not_active Application Discontinuation
- 1976-11-11 DK DK508976A patent/DK508976A/da unknown
- 1976-11-12 JP JP51135458A patent/JPS5262298A/ja active Pending
- 1976-11-12 NL NL7612639A patent/NL7612639A/xx not_active Application Discontinuation
- 1976-11-12 NL NL7612640A patent/NL7612640A/xx not_active Application Discontinuation
- 1976-11-12 ES ES453278A patent/ES453278A1/es not_active Expired
- 1976-11-12 FR FR7634072A patent/FR2331562A1/fr active Granted
- 1976-11-12 JP JP51135457A patent/JPS5262299A/ja active Pending
- 1976-11-12 SU SU762420052A patent/SU674676A3/ru active
- 1976-11-12 SU SU762421894A patent/SU645584A3/ru active
- 1976-11-12 FR FR7634073A patent/FR2331563A1/fr active Granted
- 1976-11-12 ES ES453277A patent/ES453277A1/es not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4086225A (en) | Rifamycin compounds | |
| NO159019B (no) | Analogifremgangsmaate for fremstilling av farmakologisk aktive 6beta-hydroksyalkylpenicillansyrederivater. | |
| NO173016B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive beta-laktamderivater | |
| NO763846L (fr) | ||
| US4226765A (en) | Novel rifamycin compounds of high antibiotic activity | |
| DK165974B (da) | 6-diazo-penicillansyre-1, 1-dioxidderivater | |
| US4013680A (en) | Process for the preparation of aromatic α-keto carboxylic acids | |
| FI62098B (fi) | Foerfarande foer framstaellning av tiazolo(5,4-c)rifamycin sv och dess derivat | |
| Padmavathi et al. | Synthesis and bioassay of oxazolyl/thiazolyl selenadiazoles, thiadiazoles and diazaphospholes | |
| NO128028B (fr) | ||
| Pregnolato et al. | Synthesis of 3H‐thieno [3, 2‐c]‐1, 2‐dithiole‐3‐thione and its reaction with n‐butylamine | |
| Ogura et al. | The Reaction of Aminotropones with Diketene. I. On the Synthesis of 3-Acetyl-1-azaazulenes and Related Reactions | |
| Gubelt et al. | Oxidation with lead tetraacetate. IV. Cyclization of phenylhydrazones of levulinic acid, levulinanilide, 5-ketohexanoic acid, 4-keto-1-pentanol, and of levulinic acid oxime | |
| Klásek et al. | Conversion of 3‐hydroxy‐1, 2, 3, 4‐tetrahydroquinoline‐2, 4‐diones to 2, 3a, 4, 5‐tetrahydrofuro [2, 3‐c] quinoline‐2, 4‐diones via an intramolecular wittig reaction | |
| Yates et al. | Photodimeric cage compounds. V. Transformations of the dioximes of the photodimers of 2, 6-dimethyl-and 2, 6-diethyl-4-pyrone | |
| JPS58225093A (ja) | ベンゾチアジノリフアマイシン誘導体およびその製造法 | |
| KR810000103B1 (ko) | 리파마이신 화합물의 제조방법 | |
| KR820000498B1 (ko) | 리파마이신 화합물의 제조방법 | |
| Girges et al. | Synthesis of some new 3-substituted-4-hydroxy-1-methyl-quinolin-2-one derivatives as potential antibacterial and antifungal agents | |
| Löwe et al. | Syntheses and properties of selenium‐bridged bischromones | |
| KR790001261B1 (ko) | 리파 마이신 화합물의 제조방법 | |
| US4217276A (en) | Rifamycin compounds | |
| SU578889A3 (ru) | Способ получени производных пенициллинов или цефалоспоринов, или их солей или их эфиров | |
| FI71740B (fi) | Vid framstaellning av terapeutiskt aktiv penicillansyra-1,1-dioxid saosom mellanprodukter anvaendbara i penicillansyra-1-oxider | |
| SU429062A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ПИРИДО[2,3-Ь] [1,5]ТИАЗЕПИНОНОВПредлагаетс способ получени пиридо [2,3-й] [!1,5]тиазепиионов, которые могут найти применение в качестве биологически активных веществ.В литературе нет сведений о получении производных указанной гетероциклической сисге- мы. Известны лишь производные пиримидо [i2,5-&] ['1,5]тиазепинона, способ получени которых основан на реакции 5-амино-6-меркапто- пиримидинов с хлорангидридом р-бромпропио- новой кислоты с последующей циклизацией образующихс при этом 5-(р-бромпропионил) амино-6-меркаптопиримидинов и пиримидоти- азепины.Оказалось, что этим методом нельз получить пиридотиазепиноны, так как реакци 2-меркапто-З-аминопиридинов с хлорангидридом р-бромн|ропионовой кислоты протекает одновременно по амино- и меркаптогруппе, в результате чего образуютс соединени , от которых не удаетс перейти к пиридотиазепино- нам.Предлагаетс способ получени ииридо [2,3-6] [1,5]тиазепинонов общей формулы 1Ri , , I ^',N—<где R — водород, алкоксил или галоид;RI — водород или алкил. Способ заключаетс в том, что 2-меркапто- 3-аминопиридин общей формулы 2IN'H,SH1015где R имеет указанные значени , нодвер- гают взаимодействию с р-галогеналкановой кислотой в среде растворител , например спирта, в присутствии гидроокисей щелочных металлов, полученный при этом 2-(|р-карбо- кснэтил)тио-3-аминопиридин общей формулы 320иf^^^^-I II г- СООНV-s-^2530где R имеет указанные значени , цикли- зуют под действием дициклогексилкарбоди- имида в среде растворител и образовавшиес целевые соединени формулы 1, где Ri — водород, или выдел ют обычными нриемами или, если это необходимо, далее перевод т в целевые соединени общей формулы 1, где Ri •— алкил, действием галоидалкилов, например |